Search Results - "Hesselink, D."

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized‐Controlled Clinical Trials by Bouamar, R., Shuker, N., Hesselink, D. A., Weimar, W., Ekberg, H., Kaplan, B., Bernasconi, C., Gelder, T.

“…Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration–effect relationship for Tac is poorly defined. This…”
Get full text

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients by Andrews, L. M., Hesselink, D. A., Schaik, R. H. N., Gelder, T., Fijter, J. W., Lloberas, N., Elens, L., Moes, D. J. A. R., Winter, B. C. M.

“…Aims The aims of this study were to describe the pharmacokinetics of tacrolimus immediately after kidney transplantation, and to develop a clinical tool for…”
Get full text

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations by Tang, J T, Andrews, L M, van Gelder, T, Shi, Y Y, van Schaik, R H N, Wang, L L, Hesselink, D A

“…Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and…”
Get more information

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation by Shuker, N., Bouamar, R., Schaik, R. H. N., Clahsen‐van Groningen, M. C., Damman, J., Baan, C. C., Wetering, J., Rowshani, A. T., Weimar, W., Gelder, T., Hesselink, D. A.

“…Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This…”
Get full text

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients by Francke, M. I., Visser, W. J., Severs, D., de Mik - van Egmond, A. M. E., Hesselink, D. A., De Winter, B. C. M.

“…Purpose A population pharmacokinetic (popPK) model may be used to improve tacrolimus dosing and minimize under- and overexposure in kidney transplant…”
Get full text

Follicular T helper cells and humoral reactivity in kidney transplant patients by de Graav, G. N., Dieterich, M., Hesselink, D. A., Boer, K., Clahsen‐van Groningen, M. C., Kraaijeveld, R., Litjens, N. H. R., Bouamar, R., Vanderlocht, J., Tilanus, M., Houba, I., Boonstra, A., Roelen, D. L., Claas, F. H. J., Betjes, M. G. H., Weimar, W., Baan, C. C.

“…Summary Memory B cells play a pivotal role in alloreactivity in kidney transplantation. Follicular T helper (Tfh) cells play an important role in the…”
Get full text

The SElf-Care After REnal Transplantation Study: A Retrospective Evaluation of a Home-Monitoring Program Implemented as Standard Care by Hezer, B, Reinders, M E J, van den Hoogen, M W F, Tielen, M, van de Wetering, J, Hesselink, D A, Massey, E K

“…After transplantation self-management is essential for graft survival and optimal quality of life. To address the need for home-based support in…”
Get full text

Systematic review of surgical and medical treatment for tertiary hyperparathyroidism by Dulfer, R. R., Franssen, G. J. H., Hesselink, D. A., Hoorn, E. J., van Eijck, C. H. J., van Ginhoven, T. M.

“…Background A significant proportion of patients with chronic kidney disease and secondary hyperparathyroidism (HPT) remain hyperparathyroid after kidney…”
Get full text

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus by Hesselink, Dennis A., Schaik, Ron H. N., Heiden, Ilse P., Werf, Marloes, Gregoor, Peter J. H. Smak, Lindemans, Jan, Weimar, Willem, Gelder, Teun

“…Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have a narrow therapeutic index and show considerable interindividual…”
Get full text

Personalized immunosuppression in elderly renal transplant recipients by Peeters, L.E.J., Andrews, L.M., Hesselink, D.A., de Winter, B.C.M., van Gelder, T.

“…[Display omitted] The number of elderly people has increased considerably over the last decades, due to a rising life expectancy and ageing populations. As a…”
Get full text

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial by Peeters, Laura E J, Kappers, M H W, Hesselink, D A, van der Net, J B, Hartong, S C C, van de Laar, R, Ezzahti, M, van de Ven, P J G, van der Meer, I M, de Bruijne, E L E, Kroon, A A, Indhirajanti-Tomasoa, S, van der Linde, N A J, Bahmany, S, Boersma, E, Massey, E K, van Dijk, L, van Gelder, T, Koch, Birgit C P, Versmissen, Jorie

“…Adherence to antihypertensive drugs (AHDs) is crucial for controlling blood pressure (BP). We aimed to determine the effectiveness of measuring AHD…”
Get full text

The prevalence of osteopenia and osteoporosis after heart transplantation assessed using CT by Roest, S., Budde, R.P.J., Hesselink, D.A., Zijlstra, F., Zillikens, M.C., Caliskan, K., Bos, D., Manintveld, O.C.

“…Osteoporosis is frequently observed in patients after heart transplantation (HT), although the prevalence long-term post-HT is unknown. Most studies…”
Get full text

Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection by de Leur, K., Clahsen‐van Groningen, M. C., van den Bosch, T. P. P., de Graav, G. N., Hesselink, D. A., Samsom, J. N., Baan, C. C., Boer, K.

“…Summary We hypothesize that T cells such as interleukin (IL)‐21+B cell lymphoma 6 (BCL6)+ T follicular helper cells can regulate B cell‐mediated immunity…”
Get full text

Circulating endothelial cells transiently increase in peripheral blood after kidney transplantation by Tejeda-Mora, H., Verhoeven, J. G. H. P., Verschoor, W., Boer, K., Hesselink, D. A., van den Hoogen, M. W. F., van der Laan, L. J. W., Baan, C. C., Minnee, R. C., Hoogduijn, M. J.

“…The diagnosis of kidney allograft rejection is based on late histological and clinical markers. Early, specific and minimally-invasive biomarkers may improve…”
Get full text

Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients by de Boer, S E, Sanders, J S F, Bemelman, F J, Betjes, M G H, Burgerhof, J G M, Hilbrands, L, Kuypers, D, van Munster, B C, Nurmohamed, S A, de Vries, A P J, van Zuilen, A D, Hesselink, D A, Berger, S P

“…In 2019, more than 30 % of all newly transplanted kidney transplant recipients in The Netherlands were above 65 years of age. Elderly patients are less prone…”
Get full text

The mast cell: A Janus in kidney transplants by van der Elst, G, Varol, H, Hermans, M, Baan, C C, Duong-van Huyen, J P, Hesselink, D A, Kramann, R, Rabant, M, Reinders, M E J, von der Thüsen, J H, van den Bosch, T P P, Clahsen-van Groningen, M C

“…Mast cells (MCs) are innate immune cells with a versatile set of functionalities, enabling them to orchestrate immune responses in various ways. Aside from…”
Get full text

Corrigendum: The mast cell: A Janus in kidney transplants by van der Elst, G, Varol, H, Hermans, M, Baan, C C, Duong-van Huyen, J P, Hesselink, D A, Kramann, R, Rabant, M, Reinders, M E J, von der Thüsen, J H, van den Bosch, T P P, Clahsen-van Groningen, M C

“…[This corrects the article DOI: 10.3389/fimmu.2023.1122409.]…”
Get full text

Practicability of Pharmacogenetics in Transplantation Medicine by van Gelder, T, van Schaik, R H, Hesselink, D A

“…Implementation of pharmacogenetics in transplantation medicine has not met the expectations expressed 15 years ago. Numerous studies have reported associations…”
Get full text

Treatment of Steroid‐Resistant Acute Renal Allograft Rejection With Alemtuzumab by van den Hoogen, M. W. F., Hesselink, D. A., van Son, W. J., Weimar, W., Hilbrands, L. B.

“…Steroid‐resistant renal allograft rejections are commonly treated with rabbit antithymocyte globulin (RATG), but alemtuzumab could be an effective, safe and…”
Get full text

Seen from the moon we are all the same size: Deceased donation in the Netherlands by Hesselink, D A, Weimar, W

Get full text